RT Journal Article
SR Electronic
T1 Countries should aim to lower the reproduction number ℛ close to 1.0 for the short-term mitigation of COVID-19 outbreaks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20065268
DO 10.1101/2020.04.14.20065268
A1 Hochberg, Michael E.
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065268.abstract
AB The COVID-19 pandemic is still in its early stages and given the speed and magnitude of local outbreaks it is urgent to understand how mitigation measures translate into changes in key epidemiological and clinical outcomes. Here, we employ a mathematical model to explore the short-term consequences of lowering the reproduction number ℛ0 and delaying measures on total infections and fatalities. The positive implications of mitigation generally accrue as these measures are adopted early, with the most striking effects seen when the reproductive number is lowered to a level ℛC≈1.0. As the delay in adopting measures exceeds approximately the half-way point to the peak of an outbreak, the effects of lowering ℛ0 markedly decrease. Aiming for reproduction numbers close to 1.0 can substantially reduce fatality probabilities over short time scales, particularly for larger populations. We conclude that research is urgently needed on how mitigation measures impact ℛ0 and how these can be optimized so as to achieve ℛC≈1.0 whilst supporting individual freedoms, society and the economy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEpidemic simulator code provided in Supp Material